

Heather Margaret Wilson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3460788/publications.pdf>

Version: 2024-02-01

39
papers

1,262
citations

471371
17
h-index

377752
34
g-index

40
all docs

40
docs citations

40
times ranked

2006
citing authors

#	ARTICLE	IF	CITATIONS
1	Diabetes mellitus and Parkinson disease. <i>Neurology</i> , 2018, 90, e1654-e1662.	1.5	158
2	Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson's disease. <i>Brain</i> , 2018, 141, 1501-1516.	3.7	148
3	REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. <i>Neurology</i> , 2018, 91, e894-e905.	1.5	112
4	Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo ¹¹ C-BU99008 PET study. <i>Brain</i> , 2019, 142, 3116-3128.	3.7	73
5	Serotonergic pathology and disease burden in the premotor and motor phase of A53T α -synuclein parkinsonism: a cross-sectional study. <i>Lancet Neurology</i> , The, 2019, 18, 748-759.	4.9	70
6	Serotonergic dysregulation is linked to sleep problems in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2018, 18, 630-637.	1.4	52
7	Cortical thinning across Parkinson's disease stages and clinical correlates. <i>Journal of the Neurological Sciences</i> , 2019, 398, 31-38.	0.3	51
8	Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle ² A in Early Drug-Naive Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1416-1427.	2.2	48
9	Molecular Imaging Markers to Track Huntington's Disease Pathology. <i>Frontiers in Neurology</i> , 2017, 8, 11.	1.1	44
10	Aquaporin-4 polymorphisms predict amyloid burden and clinical outcome in the Alzheimer's disease spectrum. <i>Neurobiology of Aging</i> , 2021, 97, 1-9.	1.5	40
11	Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. <i>Journal of the Neurological Sciences</i> , 2016, 368, 243-248.	0.3	37
12	A Specialized Niche in the Pancreatic Microenvironment Promotes Endocrine Differentiation. <i>Developmental Cell</i> , 2020, 55, 150-162.e6.	3.1	37
13	Chronic exposure to dopamine agonists affects the integrity of striatal D 2 receptors in Parkinson's patients. <i>NeuroImage: Clinical</i> , 2017, 16, 455-460.	1.4	33
14	Dementia spectrum disorders: lessons learnt from decades with PET research. <i>Journal of Neural Transmission</i> , 2019, 126, 233-251.	1.4	32
15	Loss of phosphodiesterase 4 in Parkinson disease. <i>Neurology</i> , 2017, 89, 586-593.	1.5	30
16	Disease-related patterns of in vivo pathology in Corticobasal syndrome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2413-2425.	3.3	26
17	Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases. <i>Cells</i> , 2020, 9, 2581.	1.8	20
18	Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications. <i>Journal of Neurology</i> , 2020, 267, 2042-2053.	1.8	20

#	ARTICLE	IF	CITATIONS
19	[18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 366-378.	3.3	19
20	Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 141, 131-172.	0.9	18
21	Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 541-560.	1.2	18
22	Neuroimaging of Sleep Disturbances in Movement Disorders. <i>Frontiers in Neurology</i> , 2018, 9, 767.	1.1	15
23	Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1505-1515.	2.2	15
24	Imaging the Nonmotor Symptoms in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 179-257.	0.9	14
25	Structural Magnetic Resonance Imaging in Huntington's Disease. <i>International Review of Neurobiology</i> , 2018, 142, 335-380.	0.9	14
26	Hybrid PET-MRI Applications in Movement Disorders. <i>International Review of Neurobiology</i> , 2019, 144, 211-257.	0.9	14
27	Predictors of RBD progression and conversion to synucleinopathies. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 93-104.	2.0	13
28	Nucleus basalis of Meynert degeneration predicts cognitive impairment in Parkinson's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 179, 189-205.	1.0	12
29	The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 163-169.	1.1	11
30	Serotonergic imaging in Parkinson's disease. <i>Progress in Brain Research</i> , 2021, 261, 303-338.	0.9	11
31	Molecular Imaging of Dementia With Lewy Bodies. <i>International Review of Neurobiology</i> , 2019, 144, 59-93.	0.9	10
32	The postnatal pancreatic microenvironment guides β^2 cell maturation through BMP4 production. <i>Developmental Cell</i> , 2021, 56, 2703-2711.e5.	3.1	10
33	Urinary dysfunction in early de novo patients with Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 939-940.	2.2	9
34	Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson's disease. <i>BMC Neuroscience</i> , 2019, 20, 55.	0.8	9
35	Imaging Transplantation in Movement Disorders. <i>International Review of Neurobiology</i> , 2018, 143, 213-263.	0.9	6
36	Molecular Imaging in Huntington's Disease. <i>International Review of Neurobiology</i> , 2018, 142, 289-333.	0.9	6

#	ARTICLE	IF	CITATIONS
37	Predict cognitive decline with clinical markers in Parkinson's disease (PRECODE-1). Journal of Neural Transmission, 2020, 127, 51-59.	1.4	6
38	Recent Advances in Neuroimaging Techniques to Assist Clinical Trials on Cell-Based Therapies in Neurodegenerative Diseases. Stem Cells, 2022, 40, 724-735.	1.4	1
39	Imaging in Huntington's. Neuromethods, 2022, , 457-505.	0.2	0